Skip to main content
Fig. 4 | BMC Nephrology

Fig. 4

From: Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials

Fig. 4

Forest plot of the effect of CRP levels on the efficacy of HIF-PHIs subgroup by previous ESA usage. A Random-effect model; B Fixed-effect model. CRP: c-reactive protein; ULN, upper limit of normal; ESA, erythropoiesis-stimulating agents; Mean, mean change of Hb from baseline to end of treatment, g/dl; SD, Standard deviation; CI: confidence interval; Total: Total number of patients in the study group; df: degrees of freedom; I2, I-squared

Back to article page